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The pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α) is 
associated with malarial virulence (disease severity) in both rodents and humans. We are 
interested in whether parasite genetic diversity influences TNF-mediated effects on 
malaria virulence. Here, primary infections with genetically distinct Plasmodium 
chabaudi chabaudi (P.c.c.) clones varied in the virulence and cytokine responses induced 
in female C57BL/6J mice. Even when parasitaemia was controlled for, a greater day 7 
TNF-α response was induced by infection with more virulent P.c.c. clones. Since many 
functions of TNF-α are exerted through TNF receptor 1 (TNFR1), a TNFR-1 fusion 
protein (TNFR-Ig) was used to investigate whether TNFR1 blockade eliminated clone 
virulence differences. We found that TNFR-1 blockade ameliorated the weight loss, but 
not the anemia induced by malaria infection, regardless of P.c.c. clone. We show distinct 
P.c.c. infections induced significantly different plasma interferon gamma (IFN-), 
interleukin 6 (IL-6) and interleukin 10 (IL-10) levels. Our results demonstrate that 
regardless of P.c.c. genotype, blocking TNFR1 signalling protected against weight loss, 
but had negligible effects on both anemia and asexual parasite kinetics. Thus, during 
P.c.c. infection, TNF-α is a key mediator of weight loss, independent of parasite load and 
across parasite genotypes. 
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Malaria represents an enormous global health problem, causing immense 
morbidity and mortality (defined here as virulence) worldwide (Snow et al. 2005). 
Malaria infection causes a wide spectrum of virulence, resulting in an estimated 2 million 
deaths each year (Alles H K 1998). We are interested in understanding the causes of this 
variation in virulence. Both field and rodent studies have shown that while some 
virulence is directly linked to parasite load (Langhorne et al. 1998; Mackinnon & Read 
2004), some is immunopathological, arising as a result of the host’s immune response to 
the parasite (Dodoo et al. 2002; Torre et al. 2002). The ‘cytokine theory’ of malaria, for 
example, hypothesizes that cytokines contribute to disease (Clark et al. 2004), and the 
potent pro-inflammatory cytokine tumor necrosis factor alpha (TNF-α) has been shown 
to have dual roles in malaria infection: inhibiting in vivo parasite growth and controlling 
infection on the one hand (Jacobs et al. 1996; Langhorne et al. 1989; Li & Langhorne 
2000; Sam et al. 1999; Stevenson et al. 1995), while causing immune-mediated disease 
on the other (Clark & Chaudhri 1988a; Clark & Chaudhri 1988b; Grau et al. 1987; Kern 
et al. 1992).  
We are particularly interested in whether host immune response contributes to the 
different virulence outcomes induced by genetically distinct P.c.c. infections. Studies 
using Plasmodium chabaudi chabaudi (P.c.c.), the immunologically best characterized 
rodent model of malaria, have focused largely on a single clone: AS (Jacobs et al. 1996; 
Langhorne et al. 1989; Li & Langhorne 2000; Sam et al. 1999; Stevenson et al. 1995). 
However, primary infections by other P.c.c. clones have been shown to induce a 
spectrum of virulence phenotypes in a given inbred mouse strain supporting a role for 




parasite strain in virulence determination (Ferguson et al. 2003; Mackinnon & Read 
1999a; Mackinnon & Read 1999b). Strain-specific variation in malaria virulence during 
human P. falciparum infections has also been reported (Chotivanich et al. 2000; 
Gravenor et al. 1995). Because high serum TNF-α concentrations are associated with 
severe infection (Grau et al. 1989; Molyneux et al. 1993; Molyneux et al. 1991) and 
malaria parasites directly stimulate the production of TNF-α from macrophages (Bate & 
Kwiatkowski 1994; Bate et al. 1992; Bate et al. 1988; Bate et al. 1989), we hypothesized 
that parasite genetic differences in induction of systemic TNF-α may contribute to clone 
differences in virulence. For example, distinct P.c.c. clones may achieve high virulence 
by (i) growing to high parasite densities in the host, (ii) inducing a large TNF-α response, 
or (iii) through a combination of these factors. 
Ignoring the role parasite genotype plays in determining immune-mediated 
virulence may lead to conclusions which are parasite strain- or clone-specific. In the field 
of Leishmania, the role mouse strain played in disease outcome was the initial focus and 
led to conflicting data until it was recognized that parasite genotype could help to explain 
reported differences in disease outcome (Kebaier et al. 2001; Ritter et al. 2004). For 
example, infection with a range of L. major strains in BALB/c mice resulted in distinct 
immune responses and a spectrum of virulence, from asymptomatic to visceral 
leishmaniasis (Kebaier et al. 2001). In addition, the anaemia induced during rodent 
Trypanosoma infections (Naessens et al. 2005) and the outcome of toxoplasmosis in 
rodent models (Mordue et al. 2001) have been shown to depend on the immune response 
induced by the particular host-parasite combination. For malaria, numerous studies have 
shown that mouse strains vary in their ability to control and clear primary infections (Li 




et al. 2001). However, immunological analysis of the role of parasite strain in 
determining the outcome of malaria has largely been overlooked, with the majority of 
rodent studies focusing on a single parasite strain or clone from a given Plasmodium 
species.  
In the present study, we took two approaches to understand the role TNF-α plays 
in response to infection with distinct malaria genotypes. First, we investigated whether 
the level of virulence induced by the genetically distinct P.c.c clones correlated with a 
specific host cytokine response. We found that more virulent clones induced a greater 
plasma TNF-α response. To directly test whether the induction of a large TNF-α 
response is the reason some clones are more virulent, we then blocked TNF-α signalling 
by administering a soluble form of the TNF Receptor 1 (TNFR-Ig) and followed in vivo 
virulence, parasite dynamics and cytokine responses during distinct P.c.c. infections. We 
found that blocking TNFR-1 signalling protected against weight loss, but the level of 
protection did not differ among clones.  
 
MATERIALS AND METHODS 
Mice and parasites 
Plasmodium chabaudi chabaudi (P.c.c.) clones were originally derived from thicket rat 
isolates and cryopreserved (Walliker et al. 1971). Clones are stored as frozen stabilities, 
with subscript codes denoting their exact clonal history. In both experiments we used the 
following clones; CW640, AS11915, BC200 and AJ4762 (herein referred to as CW, AS, BC 
and AJ). These four genetically distinct P.c.c. clones were selected based on the range of 
virulence they induce in C57BL/6 female mice; clones BC & AJ are virulent and clones 




AS & CW substantially less virulent in terms of weight and red blood cell loss 
(Mackinnon & Read 1999a).  Clone differences in virulence are maintained across mouse 
strain (de Roode et al. 2005; Mackinnon et al. 2002). In both experiment one and two, 
hosts were 6-8 week old female inbred C57BL/6 mice (Harlan, U.K. or bred at animal 
facilities of the University of Edinburgh, respectively). Mice were housed in filter-top 
cages, maintained in a 12hr:12hr light-dark cycle, fed 41B maintenance diet (Harlan, 
U.K.) and their drinking water was supplemented with 0.05% para-amino benzoic acid 
(Jacobs 1964).  
 
Experimental design, parasite inoculation and in vivo antibody treatment 
Infections were initiated with an i.p. injection of 0.1ml inoculum containing 10
6
 red blood 
cells (RBCs) parasitized by one of the above four malaria clones. The inoculum was 
prepared from parasite donor mice through the dilution of infected blood in calf serum 
solution (50% Ringer’s solution [27mM KCL, 27mM CaCl2, 0.15M NaCl], 50% heat-
inactivated calf-serum, 20 units heparin/ml mouse blood). Control mice received a 0.1ml 
inoculum of 10
6 
naïve RBCs and were subject to the same treatment regimes as 
experimental mice.   
In experiment one, we investigated whether clone differences in malaria virulence 
could be explained by differences in plasma levels of TNF-α, interleukin [IL]-6, IL-
12p70, IL-10 or interferon [IFN]- in unmanipulated hosts on days 2, 5 or 7 post infection 
(p.i.). Three mice per parasite clone were sacrificed at each time-point and plasma was 
collected for cytokine measurement. These time-points have  previously been associated 




with protective or pathological cytokine responses in P.c.c. AS infections (Li et al. 1999; 
Li et al. 2003; Sam & Stevenson 1999; Su & Stevenson 2002).  
In experiment two, the effect of blocking TNFR1 signalling on infection 
dynamics was investigated via the administration of a soluble TNF Receptor. Soluble 
TNF Receptor 1 (herein referred to as TNFR-Ig) has been shown to bind and efficiently 
inhibit mouse TNF-α activity in vivo (Ashkenazi et al. 1991) and was kindly provided by 
the Therapeutic Antibody Centre, University of Oxford (Oxford, UK). Malaria infections 
were initiated as in experiment one and mice were intra-muscularly injected with 75µg of 
either TNFR-Ig or an isotype control human purified IgG1 (Sigma) dissolved in sterile 
PBS (Gibco) on days 5, 6, 7 and 8 p.i. (5 mice per clone, per antibody treatment). Data on 
control mice from experiment two replicated our results from experiment one. TNFR-Ig 
treatment was started on day 5 post infection in order to minimize interference with the 
anti-parasitic effect of TNF-α early in infection (Langhorne et al. 1989; Stevenson & 
Tam 1993).  
 
Monitoring parasitaemia and virulence 
Daily thin blood smears were made from tail blood and after Giemsa staining, the 
proportions of RBCs parasitized (parasitaemia) were counted microscopically using 
×1000 magnification. RBCs were counted until 20 parasites were detected in two or more 
separate fields of vision. This method has been shown mathematically to eliminate the 
bias in estimates of parasitemias which arises for statistical reasons when parasites are 
rare on smears (Crooks 2004). RBC densities were obtained by flow cytometery 
(Beckmann Coulter) from a 1:40,000 dilution of a 2µl sample of tail blood in Isoton 




solution every day p.i. in experiment one and on days 0, 2, 4, days 5-12 and then every 2 
days until day 21 p.i. in experiment two, when mice were sacrificed.  Mouse weights 
were recorded to the nearest 0.1g on those days p.i. indicated above.  
 
Plasma cytokine detection.  
In experiment one, blood from individual mice was collected into heparinized tubes on 
the day of sacrifice (days 2, 5 or 7 p.i.). In experiment two, 50µl of tail-blood from 
individual mice was collected into 50µl heparin (Sigma) on day 7 p.i. Blood was kept on 
ice and centrifuged at 500 × g for 10 minutes (4oC) to obtain plasma which was frozen at 
-20
o
C until the day of assay. Plasma levels of the cytokines TNF-α, IL-12p70, IL-6, IFN-
 and IL-10 were detected using a flow cytometric cytokine bead array (BD
TM
 CBA 
Array), with slight modifications from manufacturer’s instructions (BD Biosciences). 
Briefly, 50µl of plasma sample or standard were incubated in flat-bottomed 96-well 
plates (Costar®) with 25µl of cytokine capture bead mixture (anti-cytokine-coated 
microspheres) in darkness, with shaking for one hour at room temperature. Wells were 
then washed with 200µl wash buffer (1×PBS solution) and plates were spun at 200 × g 
for 5 minutes. Samples and standards were incubated with 25µl PE detection reagent 
(phycoerythrin-conjugated anti-mouse cytokine antibodies) in darkness for one hour. 
Wells were then washed and beads re-suspended in 200µl wash buffer and analysed on 








Statistical Analysis.  
Traits fell into three categories: virulence traits (live-weight and anaemia), parasite traits 
(parasitaemia) and immunological traits (plasma cytokines). The minimum live-weight 
and RBC counts reached over the course of infection were used as virulence parameters 
for analysis of both experiments. Parasite load was quantified as the maximum asexual 
parasitaemia. In experiment one, parasite and virulence data from only the mice which 
experienced the full course of infection were analysed. Maximum plasma cytokine 
concentrations were analysed for all mice in that experiment. In experiment two, 
parasitaemia and anaemia observed after the cessation of treatment (days 9 through 16 
p.i. inclusive) were also analysed and are referred to as the average post-treatment RBC 
count or parasitaemia. Finally, immunological data from experiment two (day 7 plasma 
cytokine concentrations) were analysed.  Prior to statistical analysis, it was necessary to 
transform the data to meet the necessary normality and homogeneity-of-variances 
assumptions (Grafen & Hails 2002). Box-Cox transformations were carried out on all 
non-normal data as an exploratory tool to help determine the optimal transformation 
required for normalization. In experiment one, all cytokine and RBC density data were 
log10 transformed prior to analysis, while in experiment two, the weight, IL-12p70 and 
IFN-γ data were square root transformed, the parasitemia, IL-6 and IL-10 data were 
natural log transformed and the RBC parameters were inverse square root transformed. 
Wherever possible, data are presented in their original units for intuitive ease. 
All traits mentioned above were analysed using Analysis of Variance (ANOVAs) 
or Covariance (ANCOVAs) in MINITAB (release 14, MINITAB Inc.). Explanatory 
variables for clone, treatment and an interaction between those terms were fitted to the 




data. Clone had up to five factor levels (CW, AS, BC, AJ and Naïve) depending on the 
analysis, and in experiment two, treatment had two factor levels (huIgG1 and TNFR-Ig). 
For all models, we first fitted the maximal model including covariate when relevant, and 
minimal models were obtained by removing non-significant terms (P-value > 0.05). We 
report F values and the test statistic for ANOVA as well as P values, as is essential for 
full statistical disclosure (Olsen 2003). Naïve (uninfected) mice suffered significantly less 
virulence and induced significantly lower cytokine titres relative to infected mice groups 
regardless of clone, and so were removed from the analyses. To control for the role 
parasite load may play in determining virulence, a separate analysis was carried out 
which included maximum parasitaemia as a covariate. Finally, we tested the directional 
hypothesis that clone virulence increases with increasing pro-inflammatory response 
(TNF-α  or IFN- :IL-10) using an ordered heterogeneity test (Rice & Gaines 1994). The 
OH test combines the P value from the appropriate ANOVA (Pc) with the Spearman’s 
rank correlation coefficient (rs) to calculate the test statistic (rsPc) as follows: rsPc =r × (1 
- P ) (Rice & Gaines 1994). 
  
RESULTS 
Experiment one: clone-specific induction of TNF-α. 
 Wild type C57BL/6 female hosts were infected with 106 parasites of one of four 
genetically distinct P.c.c. clones; denoted CW, AS, BC and AJ. One mouse died during 
the experiment and was removed from the analyses (AJ infected mouse on day 13 p.i.). 
The course of these distinct primary infections, including the virulence and cytokine 
responses they induced, were examined. Maximum asexual parasitaemias did not differ 




significantly between clones (Fig. 1A; clone: F3,8 = 1.7, P > 0.05).  However, clone 
differences in virulence were found, with clones AJ and BC inducing lower minimum 
weight and RBC densities than CW or AS infections (Fig. 1B; clone: F3,7 = 11, P < 0.01; 
and Fig. 1C; clone: F3,8 = 6, P < 0.05, respectively). These clone differences in weight 
and RBC loss agree with previous studies (Mackinnon & Read 1999a; Mackinnon & 
Read 1999b; Mackinnon & Read 2004) and were maintained even when controlling for 
parasite load (clone: F3,6 = 10, P < 0.01; and clone: F3,7 = 10, P < 0.01, respectively). 
Hence, the virulence differences observed between clones are not simply a consequence 
of parasite burden.  
Clones differed in the cytokine profile they induced over time, with significant clone 
differences in day 5 IFN- levels, as well as day 7 TNF-α and IL-6 levels (Fig. 2A; clone: 
F3,8 = 14, P < 0.001; Fig. 2B; clone: F3,8 = 5.4, P < 0.05 and Fig. 2C; clone: F3,8 = 7.2, P < 
0.05). The most virulent clones, AJ and BC, induced high concentrations of pro-
inflammatory cytokines: both induced TNF-α; BC also induced IFN- , while AJ induced 
IL-6 (Fig. 2A, B and C). A trend was observed whereby IL-10 levels were elevated 
during infection with avirulent clones on day 5 p.i., but this was not significant (Fig. 2D; 
clone: F3,8 = 1.2, P < 0.4). Although clone differences in plasma cytokine profiles were 
found, only the amount of TNF-α induced on day 7 p.i. correlated with clone differences 
in virulence (Fig. 2A; clone: F3,8 = 5, P < 0.05, rsPc = 0.97, P < 0.01; and controlling for 
average parasitaemia; clone: F3,7 = 6, P < 0.05, rsPc = 0.97, P < 0.01). Thus, it is possible 
that clone differences in TNF-α induction around the peak of parasitaemia can help 








Experiment two: effect of blocking TNFR1 signalling during genetically distinct malaria 
infections 
TNFR1 signalling was blocked via the administration of a soluble TNF receptor 1 fusion 
protein (TNFR-Ig) during each of four distinct P.c.c. infections (as above) and in vivo 
virulence, parasite dynamics and host plasma cytokine response were followed 
throughout infection. Three mice died during the experiment and were removed from our 
analyses (two IgG treated, AJ infected mice and one TNFR-Ig treated, BC infected mouse 
on days 10 and 11 p.i.). 
 
(i) Virulence 
In vivo blocking of TNFR1 signalling protected mice against malaria-induced weight loss 
(Fig. 3A, B; treatment: F1,28 = 7, P < 0.01). As observed above, clone differences in 
weight loss were found (Fig. 3B; clone: F3,28 = 13, P < 0.001), but the level of protection 
conferred by treatment did not vary among clones (Fig 3B; clone × treatment: F3,28 = 2, P 
= 0.2). For example, the protection from weight loss the TNFR-Ig treatment afforded to 
AS infected mice did not differ significantly from that afforded to AJ infected mice, even 
though the latter lost almost 2g more weight. Although clone differences in post-
treatment anaemia were found (Fig. 3C and D; clone: F3,28 = 3, P < 0.05), in contrast to 
weight loss, blocking TNFR1 signalling did not affect the degree of anaemia induced 
(Fig. 3D; treatment and clone × treatment: P > 0.05 in all cases). Thus, blocking TNFR1 
signalling protects against malaria-induced weight loss, but the extent of this protection 
does not vary among clones. In addition, blocking TNFR1 signalling has no effect on 
anaemia induced by any of the clones. 
Fig.3. 





(ii) Parasite Load 
For the first 8 days of infection, treatment did not significantly affect asexual parasite 
dynamics (Fig. 4A). However, after treatment stopped on day 9 p.i., depleted mice 
suffered elevated parasitaemias (Fig. 4A and B; average post-treatment parasitaemia; 
treatment: F1,29 = 7, P < 0.05). We analysed several aspects of the parasite data presented 
in Fig. 4A. While there were clone differences in average parasitaemia and day of peak 
parasitemia (Fig. 4A; clone: F3,29 = 5, P < 0.01; and clone: F3,29 = 10, P < 0.001, 
respectively) and near significant differences in both the maximum and average post-
treatment parasitaemia  (clone: F3,29 = 2, P = 0.09; and clone: F3,29 = 3, P = 0.06, 
respectively), the magnitude of these clone differences were unaffected by treatment 
(clone × treatment: P > 0.05 in all cases). Thus, blocking TNFR1 signalling had similarly 
negligible effects on parasite kinetics for all the clones. 
 
(iii) Per-parasite virulence 
To differentiate between the roles parasite load and immunopathology play in driving 
malaria virulence (Graham et al. 2005) we examined the effects of clone and treatment on 
virulence by statistically taking maximum parasitaemia into account. Although parasite 
load was a significant predictor of weight loss (F1,27 = 8, P < 0.01), it did not affect clone 
differences in weight loss, nor the protective effect of treatment on minimum weight 
(clone: F3,27 = 10, P < 0.001, treatment: F1,27 = 7, P < 0.05, clone × treatment: F3,27 = 2 P 
= 0.1). These results show that TNFR-1 signalling contributes towards malaria-induced 
weight loss, independently of parasite load or parasite genotype. Thus, the virulence 
Fig.4. 




differences among clones and treatments depicted in Fig. 3B and D are not due to 
parasitaemia differences alone. 
For a given parasite burden, TNFR-Ig treated mice suffered greater anaemia from 
day 9 p.i. onwards after treatment ended (treatment: F1,27 = 5, P < 0.05). In contrast, clone 
differences in post-treatment anaemia were removed once parasite load was taken into 
account (clone: F3,27 = 2, P = 0.2 and clone × treatment: F3,27 = 0.4, P = 0.8). Parasite load 
alone thus explains clone differences in post-treatment anaemia. 
 
(iv) Cytokines associated with immunopathology 
To examine the induction of cytokines that might contribute to the clone or treatment 
effects on virulence, we measured the levels of several plasma cytokines on day 7 p.i. 
during experiment two. Clones differed significantly in the induction of plasma IFN-, 
IL-6 and IL-10 on day 7 p.i. (Table 1). Treatment, on the other hand, only significantly 
affected plasma IL-6, with TNFR-1 blockade causing elevated IL-6 levels on day 7 p.i., 
regardless of P.c.c. clone (Table 1).  
We are interested in whether clone virulence or avirulence relates to the 
development of pro- or anti-inflammatory cytokine responses. In this regard, we found 
that controlling for parasite load, day 7 plasma IFN- levels helped to explain both the 
minimum live-weight and anaemia reached (F1,26 = 21, P < 0.001 and F1,26 = 8, P < 0.01, 
respectively). Thus, just as we investigated the role parasite load plays in driving 
virulence in the previous section, we now observe that our virulence results (Fig. 3B, D) 
relate to IFN- levels. Thus, elevated IFN- around the peak of infection may have 
detrimental virulence outcomes (Kremsner et al. 1992; Waki et al. 1992). High ratios of 
Table 1. 




pro- to anti-inflammatory cytokines have been associated with malaria virulence in the 
field (Dodoo et al. 2002). In agreement with this, our data show that the ratio of IFN- to 
IL-10 is higher for more virulent P.c.c. infections, regardless of parasite load (Fig. 5; 
clone: F3,28 = 3.2, P < 0.05; and clone: rsPc = 0.966, P < 0.01). Thus, it is possible that 
clone differences in IFN- induction, or in the regulation of IFN- by anti-inflammatory 




Malaria virulence may be induced directly by the parasite or via immune-
mediated mechanisms, which include TNF-α (Clark & Chaudhri 1988a; Clark & 
Chaudhri 1988b; Grau et al. 1987; Kern et al. 1992). For example, high levels of serum 
TNF-α correlate with poor outcome and disease severity in both rodent (Clark & 
Chaudhri 1988a; Clark & Chaudhri 1988b) and human (Kwiatkowski 1990; Kwiatkowski 
et al. 1990) malaria infections. We hypothesized that P.c.c. clones may achieve high 
virulence by (i) inducing an exacerbated TNF-α response, (ii) growing to high parasite 
densities, or (iii) via a combination of these factors.  
In experiment one, we observed that more virulent malaria clones induced higher 
day 7 plasma TNF-α levels (Fig. 2A), even when parasite load was taken into account. In 
experiment two, TNFR1 signalling was blocked during genetically distinct infections, 
with the expectation that clone virulence schedules would be differentially affected and 
possibly eliminated. However, we found that regardless of parasite genotype, blocking 
TNFR-1 signalling ameliorated weight loss (Fig. 3A and B), and had little effect on 
anaemia or parasitaemia (Fig. 3C, 3D and 4A, respectively). These data suggest that the 
Fig.5. 




contribution of TNF-α to malaria virulence does not depend on P.c.c. genotype. Thus, the 
previously reported effects of TNF-α on both the virulence and parasitaemia during P.c.c. 
AS infections (Jacobs et al. 1996; Li & Langhorne 2000; Sam et al. 1999) appear 
representative of those observed across the suite of P.c.c. clones we studied.  
Separating the pathogenic effects of an overzealous immune response from those 
of parasite burden is extremely difficult (Graham et al. 2005). By adding parasitaemia to 
statistical models, we were able to show that clone differences in the induction of plasma 
TNF-α on day 7 p.i. are not completely driven by parasite load and correlate with 
virulence. In the same respect, lethal and non-lethal P. yoelii infections have been shown 
to differ in their ability to induce early TGF-β, despite no significant differences in 
parasite load at that time (Omer et al. 2003). Furthermore, the enhanced disease severity 
of IL-10 deficient mice infected with the parasites Trypanosoma cruzi (Hunter et al. 
1997), Toxoplasma gondii (Gazzinelli et al. 1996), Helicobacter hepaticus (Kullberg et 
al. 1998) or P. chabaudi (Li et al. 1999) did not correlate with increased parasite burdens, 
but rather with an increased inflammatory response. These data suggest that for many 
parasite species, disease severity is at least partly immune-mediated and independent of 
parasite load. 
There are several possible mechanisms by which different malaria genotypes 
might induce TNF-α, independent of parasite burden. For example, it is plausible that the 
cellular source of TNF-α, or alternatively the trigger for TNF-α release, may differ 
during infections with genetically distinct parasites. It has been shown that during P.c.c 
AS infections, macrophages (Stevenson et al. 1992) and dendritic cells (Seixas et al. 
2001) can produce TNF-α upon direct stimulation by the parasite in vitro, and CD4+ T 




cells have also been shown to produce TNF-α during malaria infection (Hirunpetcharat et 
al. 1999). If P.c.c. clones differ in ability to induce these cellular responses, this could 
explain the differential amplification of TNF-α we observe in the plasma. It would be of 
interest to determine what the cellular source(s) of cytokines are during infection with our 
distinct clones, and also to examine whether clones differ in antigenicity. A substantial 
amount is currently known regarding P.c.c. AS immunology (Langhorne et al. 2004; 
Stevenson & Riley 2004), but all other P.c.c. clones await similar attention.  
Our data suggest that TNFR1 signalling is dispensable (between days 5-8 p.i.) for 
the ultimate control of malaria infection, regardless of parasite genotype. To our 
knowledge, the reagents used in this study do not distinguish between TNF-α and the 
closely related cytokine Lymphotoxin-α (LT-α), which can both signal through TNFR1 
and thus we have been cautious to attribute treatment effects to TNFR1 signalling rather 
than TNF-α itself. In any case, cytokine redundancies may help explain the relatively 
small effects of TNFR-Ig treatment. For example, IL-6 or IFN- could be compensating 
for the absence of TNFR1 signalling. It has been proposed that differences in induction of 
key anti-inflammatory cytokines, which act to down-regulate the nascent pro-
inflammatory response, may also contribute to malaria pathology (Artavanis-Tsakonas et 
al. 2003; Dodoo et al. 2002). In this regard we found ratios of plasma IFN-γ to IL-10 
correlate with clone virulence (Fig. 5). Future experiments designed to block other key 
cytokines (including IL-6 and IFN-γ), possibly in combination, during diverse malaria 
infections may reveal cytokines that differentially affect clone virulence. Finally, it is 
possible that TNFR-independent pathways for virulence determination exist, for example 
both the induction of nitric oxide (NO), or generation of reactive oxygen species have 




been implicated in the pathogenesis of severe malaria (Anstey et al. 1996; Clark et al. 
1983; Griffiths et al. 2001), and may contribute to clone virulence differences observed.  
In conclusion, our results demonstrate that blocking TNFR1 signalling protects 
against weight loss during P.c.c infections, regardless of parasite genotype or 
parasitaemia. However, a role for parasite genotype in determining the contribution of 
IFN- and IL-6-mediated pathology to virulence is not ruled out by this study. Hence, 
studies aimed at investigating the contribution of cytokine-mediated pathways to the 
virulence induced by genetically diverse malaria infections deserve further attention. 
Clearer definition of the root causes of malarial virulence, including the proportion due to 
immunopathology, would help to identify essential targets which could be used in the 
treatment of malaria. 
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TABLE 1. Effects of TNFR1 blockade and P. chabaudi clone on levels of plasma IL-6, 
IFN-γ, IL-10 and IL-12p70 on day 7 post infection 
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P < 0.05 
 
F3,29= 5 
P < 0.01 
 
F3,29= 3 







Mice were infected with 10
6
 pRBCs of one of four P.c.c clones (CW, AS, BC or AJ), 
blood was obtained from individual mice on day 7 p.i., and plasma levels of IL-6, IFN-, 
IL-10 and IL-12 p70 were determined. Data are means of five mice (± SE), per clone per 
treatment, except where deaths occurred as noted in the Results section. 
b  
Effects of clone on levels of plasma cytokines was investigated via ANOVA and 
significance tests are indicated. 
c
  TNFR-Ig treated mice had significantly higher IL-6 levels compared to control huIgG1 
mice (F1,29= 5 P < 0.05), regardless of clone. 
d
  0, values below detection limits of assay. 




 Fig.1. Effect of Plasmodium chabaudi parasite clone on the kinetics of asexual 
parasitaemia (A), minimum weight (B) and minimum RBC density (C) reached during 
genetically distinct single-clone infections. Infections were initiated with 106 RBCs 
parasitised with one of P.c.c. clone CW, AS, BC or AJ. Parasitaemia and virulence 
measurements were collected every day. Mice were sequentially sacrificed on days 2, 5, 7 
and 14 p.i. Each line represents the mean of 12, 9, 6 and 3 mice up to these time points, 
respectively (+/- SE) (A) and each bar represents the least square mean of 3 mice (+/- SE) 
(B and C).

Fig. 2. Effect of Plasmodium chabaudi parasite clone (CW, AS, BC or AJ) on the levels 
of plasma TNF-α (A), IFN- (B), IL-6 (C) and IL-10 (D). Single-clone P.c.c. infections 
were initiated and blood was obtained from individual mice on day of sacrifice (days 2, 5 
and 7 p.i.). Plasma cytokine levels were determined using a flow cytometric cytokine 
bead array (see Materials and Methods). Each bar represents the mean of 3 mice (+/- SE).
 
Fig. 3. Effect of parasite clone and TNFR-Ig treatment on the kinetics of malaria-induced 
weight and red blood cell loss. Daily or every other day, mice were weighed and red 
blood cell counts obtained. Changes in live-weight over time (A), minimum live-weight 
(B), kinetics of RBC density over time (C), and minimum RBC density (D) during the 
course of primary infection with one of four P.c.c. clones (CW, AS, BC or AJ) are shown 
for TNFR-Ig treated mice (open symbols and hatched bars) or control IgG-treated mice 
(solid symbols and solid bars). Each line or bar represents the mean of 5 mice (+/- SE), 
except where deaths occurred as noted in the results section. 
 




Fig. 4. Effect of parasite clone and TNFR-Ig treatment on the kinetics of asexual 
parasitaemia. Plots represent the percentage parasitised RBCs during infection with one 
of four P.c.c. clones (CW, AS, BC or AJ) in TNFR-Ig treated mice (open symbols) or 
control IgG-treated mice (solid symbols) (A). Bars represent the least square mean of 
post-treatment asexual parasitaemia (day 9-16 inclusive), broken down by clone and 
treatment (B). Each line or bar represents the mean of 5 mice (+/- SE), except where 
deaths occurred as noted in the results section. 
 
Fig. 5. Effect of parasite clone on the ratio of plasma IFN- to IL-10 on day 7 post-
infection, for each of four P.c.c clones (CW, AS, BC or AJ). Blood was obtained from 
individual mice on day 7 p.i. and plasma levels of IFN- and IL-10 were determined. The 
natural log transformation was applied to data to meet the necessary homogeneity-of-
variance and normality assumptions. Bars are least square mean of 5 mice per infecting 
clone (± SE), except where deaths occurred as noted in Results section. 
Fig. 1A, B & C. 
TNF- and rodent malaria genotype (G. H. Long et al)
Fig. 2A, B, C & D. 
TNF- and rodent malaria genotype (G. H. Long et al)
Fig. 3 A, B, C & D. 
TNF- and rodent malaria genotype (G. H. Long et al)
Fig. 4 A & B. 
TNF- and rodent malaria genotype (G. H. Long et al)
Fig. 5. 
TNF- and rodent malaria genotype (G. H. Long et al)
